CTOs on the Move

Iota Biosciences

www.iota.bio

 
Established in 2017, iota Biosciences was formed with a vision to change how the world monitors and treats disease. Building on award-winning `neural-dust` technology invented at the University of California, Berkeley, we are building a platform for the future of bioelectronic medicine.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.iota.bio
  • 1936 University Ave
    Berkeley, CA USA
  • Phone: 888.666.O576

Executives

Name Title Contact Details

Funding

Iota Biosciences raised $15M on 12/27/2018

Similar Companies

Nobbe Orthopedics

Nobbe Orthopedics is a Santa Barbara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Simplify Medical

Simplify Medical has developed a cervical artificial disc that optimizes MRI imaging, the preferred and most accurate modality for evaluating soft tissue in the spine, while avoiding the ionizing radiation of CT scans. The Simplify Disc incorporates advanced materials to provide a metal free solution, optimum imaging capability, and kinematics.

Applied Nutrition

Applied Nutrition is a Culver City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Little Rapids

Little Rapids Corporation is a leading manufacturer and marketer of products to the healthcare and beauty markets. Our products promote safety and sanitation, and offer convenience and comfort for professionals and their patients and clients.

www.biosig.com

BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.